Use of prucalopride in adults with chronic idiopathic constipation

References

• Mitsuhashi S, Ballou S, Jiang ZG, et al. Characterizing normal bowel frequency and consistency in a representative sample of adults in the United States (NHANES). Am J Gastroenterol. 2018;113:115–123.
   PubMed Web of Science ®Google Scholar
• Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Weaver AL, Zinsmeister AR, et al. Functional constipation and outlet delay: a population-based study. Gastroenterology. 1993;105:781–790.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095.
   PubMed Web of Science ®Google Scholar
• Nullens S, Nelsen T, Camilleri M, et al. Regional colon transit in patients with dyssynergic defecation or slow transit in patients with constipation. Gut. 2012;61:1132–1139.
   PubMed Web of Science ®Google Scholar
• Lembo A, Camilleri M. Chronic constipation. N Engl J Med. 2003;349:1360–1368.
   PubMed Web of Science ®Google Scholar
• Skardoon GR, Khera AJ, Emmanuel AV, et al. Review article: dyssynergic defaecation and biofeedback therapy in the pathophysiology and management of functional constipation. Aliment Pharmacol Ther. 2017;46:410–423.
   PubMed Web of Science ®Google Scholar
• Nelson AD, Camilleri M, Chirapongsathorn S, et al. Comparison of efficacy of pharmacological treatments for chronic idiopathic constipation: a systematic review and network meta-analysis. Gut. 2017;66:1611–1622.
   PubMed Web of Science ®Google Scholar
• Ashraf W, Park F, Lof J, et al. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9:639–647.
   PubMed Web of Science ®Google Scholar
• Dipalma JA, Cleveland MV, McGowan J, et al. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–1441.
   PubMed Web of Science ®Google Scholar
• Cinca R, Chera D, Gruss HJ, et al. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation – a comparison in a controlled environment. Aliment Pharmacol Ther. 2013;37:876–886.
   PubMed Web of Science ®Google Scholar
• Hegde SS, Eglen RM. Peripheral 5-HT4 receptors. Faseb J. 1996;10:1398–1407.
   PubMed Web of Science ®Google Scholar
• Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology. 1996;111:1281–1290.
   PubMed Web of Science ®Google Scholar
• De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99–112.
   PubMed Web of Science ®Google Scholar
• Smith WB, Mannaert E, Verhaeghe T, et al. Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study. Drug Des Devel Ther. 2012;6:407–415.
   PubMed Web of Science ®Google Scholar
• Chen X, Jiang J, Liu T, et al. Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2012;50:797–804.
   PubMed Web of Science ®Google Scholar
• Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Gut. 2008;57(SupplII):A282.
   Google Scholar
• van Schaick E, Benninga MA, Levine A, et al. Development of a population pharmacokinetic model of prucalopride in children with functional constipation. Pharmacol Res Perspect. 2016;4:e00236.
   PubMed Web of Science ®Google Scholar
• Flach S, Scarfe G, Dragone J, et al. A phase I study to investigate the absorption, pharmacokinetics, and excretion of [(14)C]prucalopride after a single oral dose in healthy volunteers. Clin Ther. 2016;38:2106–2115.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Review article: tegaserod. Aliment Parmacol Ther. 2001;15:277–289.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Ackerman MJ, Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30:e13302.
   PubMed Web of Science ®Google Scholar
• Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423:71–83.
   PubMed Web of Science ®Google Scholar
• Potet F, Bouyssou T, Escande D, et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther. 2001;299:1007–1012.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767.
   PubMed Web of Science ®Google Scholar
• De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16:603–612.
   PubMed Web of Science ®Google Scholar
• Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13:1493–1497.
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44:682–686.
   PubMed Web of Science ®Google Scholar
• Emmanuel A, Kamm M, Roy A, et al. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511–516.
   PubMed Web of Science ®Google Scholar
• Bloomfield DM, Kost JT, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008;84:475–480.
   PubMed Web of Science ®Google Scholar
• Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol. 2012;73:203–209.
   PubMed Web of Science ®Google Scholar
• Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354–360.
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347–1356.
   PubMed Web of Science ®Google Scholar
• Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16:759–767.
   PubMed Web of Science ®Google Scholar
• Miner PB Jr., Camilleri M, Burton D, et al. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. Neurogastroenterol Mot. 2016;28:1341–1348.
   PubMed Web of Science ®Google Scholar
• Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion. 2003;67:82–89.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21:1256–e117.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–2354.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–328.
   PubMed Web of Science ®Google Scholar
• Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58:357–365.
   PubMed Web of Science ®Google Scholar
• Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110:741–748.
   PubMed Web of Science ®Google Scholar
• Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil. 2012;24:999–e541.
   PubMed Web of Science ®Google Scholar
• Muller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22:991–998. e255.
   PubMed Web of Science ®Google Scholar
• Winter HS, Di Lorenzo C, Benninga MA, et al. Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr. 2013;57:197–203.
   PubMed Web of Science ®Google Scholar
• Mugie SM, Korczowski B, Bodi P, et al. Prucalopride is no more effective than placebo for children with functional constipation. Gastroenterology. 2014;147: 1285–95.e1.
   PubMed Web of Science ®Google Scholar
• Nurko S, Saps M. Treating constipation with prucalopride: one size does not fit all. Gastroenterology. 2014;147:1214–1216.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32:1113–1123.
   PubMed Web of Science ®Google Scholar
• Gilsenan A, Fortuny J, Plana E, et al. 386 - Non-interventional cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort initiating polyethylene glycol 3350 (PEG). Gastroenterology. 2018;154:S92–3.
   Web of Science ®Google Scholar
• Piessevaux H, Corazziari E, Rey E, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil. 2015;27:805–815.
   PubMed Web of Science ®Google Scholar
• Kessing BF, Smout AJ, Bennink RJ, et al. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects. Neurogastroenterol Motil. 2014;26:1079–1086.
   PubMed Web of Science ®Google Scholar
• Lei WY, Hung JS, Liu TT, et al. Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility. J Gastroenterol Hepatol. 2018;33:650–655.
   PubMed Web of Science ®Google Scholar
• Carbone F, Rotondo A, Andrews CN, et al. 1077 - A controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology. 2016;150:S213–4.
   Web of Science ®Google Scholar
• Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912–2921.
   PubMed Web of Science ®Google Scholar
• Gong J, Xie Z, Zhang T, et al. Randomised clinical trial: prucalopride, a colonic pro-motility agent, reduces the duration of post-operative ileus after elective gastrointestinal surgery. Aliment Pharmacol Ther. 2016;43:778–789.
   PubMed Web of Science ®Google Scholar
• Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19:145.
   PubMed Web of Science ®Google Scholar
• Krogh K, Jensen MB, Gandrup P, et al. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol. 2002;37:431–436.
   PubMed Web of Science ®Google Scholar
• Emmanuel AV, Kamm MA, Roy AJ, et al. Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction–a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther. 2012;35:48–55.
   PubMed Web of Science ®Google Scholar
• Vijayvargiya P, Camilleri M. Update on bile acid malabsorption: finally ready for prime time? Curr Gastroenterol Rep. 2018;20(10).
   PubMedGoogle Scholar
• Nakajima A, Seki M, Taniguchi S, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:537–547.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Kolar G, et al. Relamorelin relieves constipation and accelerates colonic transit in a phase 2, placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2015;13(2312–2319):e1.
   PubMed Web of Science ®Google Scholar
• Acosta A, Camilleri M, Busciglio I, et al. Short-term effects of relamorelin on descending colon motility in chronic constipation: a randomized, controlled trial. Dig Dis Sci. 2016;61:852–860.
   PubMed Web of Science ®Google Scholar